Inovio Biomedical Corporation has announced a research collaboration agreement with the US National Institutes of Health (NIH)’s Vaccine Research Center (VRC) to develop vaccine candidates to treat the global flu pandemic.
Inovio has announced that it will pool technologies with the VRC in a bid to rapidly advance the development of vaccine candidates for the 2009 H1N1 swine flu pandemic strains.
Go deeper with GlobalData
Under the agreement, Inovio will test the electroporation-based delivery of novel DNA vaccines against influenza during pre-clinical animal studies to measure immune and protective responses.
Inovio will provide electroporation devices and procedures based on its proprietary intradermal electroporation technology and both organisations will provide DNA vaccine plasmids involved in encoding influenza antigens.
The companies are hoping that pre-clinical evaluation based on the results of challenge studies in animal models and immunological analyses at the VRC may lead to the selection of vaccine candidates for further clinical development.
Inovio CEO Dr J Joseph Kim said that there is a public health need to rapidly develop vaccines targeting the swine origin influenza A/H1N1.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“The VRC is a world leader in vaccine research and clinical development and this agreement further expands our global collaboration network for influenza vaccines,” Kim said.
The VRC is a centre within the US National Institute of Allergy and Infectious Diseases, National Institutes of Health, which conducts research to facilitate the development of effective vaccines for human disease.
